Full-Time

Occupational Health & Wellness Director

Global

Posted on 9/11/2026

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

King of Prussia, PA, USA + 5 more

More locations: Kankakee, IL, USA | Maidenhead, UK | Boca Raton, FL, USA | Broadmeadows, Australia | Waltham, MA, USA

Remote

Likely based in the United States, with scope for the right person to be based in the Australian head office.

Master's

Category
Facilities Operations (1)
Required Skills
OSHA

Get referred to CSL

See people who can refer or advise you

Requirements
  • An advanced clinical or scientific degree, such as a Nurse Practitioner or Physician Assistant qualification, a Master's in Public Health, or a Master's in Nursing with a focus on Occupational Medicine.
  • At least 10 years of Occupational Health leadership experience in multinational or regulated industries.
  • Strong experience with U.S. injury management and workers' compensation programs.
  • Knowledge of Australian self-insurance injury management and early intervention programs.
  • Familiarity with OSHA, European occupational safety and health requirements, Australian Commonwealth Work Health and Safety law, ISO 45001 and ISO 45003, and ACGIH and NIOSH frameworks.
Responsibilities
  • Design, govern, and continuously improve a global Occupational Health strategy and operating model covering injury and workers' compensation case management, employee wellness, and Occupational Health Protection.
  • Provide injury management and workers' compensation leadership in the United States, including claims governance, medical oversight, and return-to-work integration.
  • Oversee international injury management and return-to-work frameworks, including early intervention programs and optimization of self-insurance injury management in Australia.
  • Lead employee wellness by chairing the Global Health and Wellness Committee and integrating employee wellness into the global strategy, operating model, and plan.
  • Serve as a global liaison across EHS, Human Resources, Legal and Privacy, Risk and Insurance, Business Continuity, Facilities, and site leadership to develop and implement plans that advance organizational objectives.
  • Conduct strategic assessments of operating models, including resourcing for Health and Wellness functions, and implement solutions that improve efficiency through effective use of internal and external resources.
  • Develop and implement a global Occupational Health and Wellness strategy aligned with the EHS vision.
  • Lead injury management and workers' compensation programs across the United States, Europe, and Australia, ensuring compliant handling, medical quality, and efficient claim resolution.
  • Establish global standards, clinical protocols, and industrial hygiene governance systems.
  • Lead global case management, including early communication, functional capacity evaluations, and accommodation assessments.
  • Govern Australian self-insurance injury management systems and compliance audits.
  • Oversee international early intervention programs focused on rapid triage, injury minimization, capacity, and workability function retention.
  • Lead global Occupational Health and Industrial Hygiene teams and manage external vendor performance.
  • Own global Occupational Health data systems, key performance indicators, and reporting.
Desired Qualifications
  • Experience leading a global workers' compensation transformation.
  • Experience implementing global Occupational Health digital systems.
  • Experience with environmental, social, and governance metrics and cross-cultural leadership.
  • Strategic leadership and influence.
  • Clinical and technical rigor.
  • Data-driven decision-making.
  • Change management and communication excellence.
  • Inclusive leadership and global team development.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL realized US$176 million FY26 cost savings, above target, improving margins.
  • September 10, 2026 Lancet data strengthens AUJEMFLU's case with older adults and regulators.
  • CSL's VarmX collaboration funds Phase 3 VMX-C001, expanding into urgent-surgery anticoagulation reversal.

What critics are saying

  • FY26 reported a US$2.6 billion loss after US$7.1 billion impairments and restructuring.
  • Pentagon's April 2026 flu mandate repeal cuts Seqirus demand from a major buyer.
  • CSL reported March 2026 temporary global HEMGENIX availability issues, risking treatment continuity and trust.

What makes CSL unique

  • CSL's FY26 portfolio spans plasma, gene therapy, and leading influenza vaccines.
  • HEMGENIX posted 25% FY26 growth, sustaining durable haemophilia B demand.
  • AUJEMFLU won MHRA and European Commission approval, plus Lancet superiority data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.

Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.

Yahoo Finance
May 2nd, 2026
CSL to split Seqirus vaccine unit as shares slide 50% amid restructure and cost cuts

CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.

Yahoo Finance
Apr 23rd, 2026
CSL shares hit 2017 low as Pentagon scraps flu vaccine mandate for military personnel

Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.